Related Experiment Video
Updated: Jul 25, 2025
08:55
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Published on: November 2, 2014
12.3K
VCAM-1 complements CA-125 in detecting recurrent ovarian cancer
Jin Song1,2, Lori J Sokoll3,4, Zhen Zhang3,4
1Center for Biomarker Discovery and Translation, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA. jsong20@jhmi.edu.
Clinical Proteomics
|June 25, 2023
Summary
A new two-marker panel combining CA-125 and VCAM-1 shows promise for detecting recurrent ovarian cancer. This combination significantly improves upon CA-125 alone, offering better early detection strategies.
Area of Science:
- Oncology
- Biomarker Discovery
- Immunodiagnostics
Background:
- Ovarian cancer is frequently diagnosed at advanced stages, with high rates of treatment failure and recurrence.
- Early detection of ovarian cancer recurrence is crucial for timely intervention and improved patient outcomes.
Purpose of the Study:
- To evaluate a novel two-marker panel for the early detection of recurrent ovarian cancer.
- To assess the diagnostic performance of CA-125 and VCAM-1 in distinguishing primary from recurrent ovarian tumors.
Main Methods:
- An 8-plex immunoassay using magnetic beads and a Bio-Plex 200 Suspension Array System was employed.
- Sera from 58 advanced ovarian cancer patients and 46 healthy controls were analyzed for target protein levels.
- Logistic regression modeling was used to select and evaluate biomarker panels.
Main Results:
- The 8-plex immunoassay demonstrated high analytical performance suitable for biomarker validation.
- A two-marker panel of CA-125 and VCAM-1 showed improved detection of recurrent ovarian cancer compared to CA-125 alone (AUC: 0.813 vs. 0.700).
- The panel significantly enhanced sensitivity in differentiating primary from recurrent tumors (70.8% vs. 37.5%) at 83% specificity.
Conclusions:
- The CA-125 and VCAM-1 two-marker panel exhibits strong diagnostic performance for recurrent ovarian cancer detection.
- VCAM-1 complements CA-125, offering a significant improvement over using CA-125 alone.
- Further clinical validation is warranted to establish the role of this panel in early ovarian cancer recurrence detection.
